Drug intelligence / Profile preview

ACTB1010

Development stage: Unknown
Lead developer: Eddingpharm
Modality: Small Molecules

Overview

**ACTB1010** is a small molecule inhibitor targeting Aurora kinases, which are serine/threonine kinases critical for cell cycle regulation, particularly during mitosis. Aurora kinase inhibition disrupts chromosome segregation and cytokinesis, leading to mitotic arrest and apoptosis, making it a promising approach for oncology. Developed by ACT Biotech and later acquired by Eddingpharm, it is designed for the treatment of various cancers, with preclinical data supporting antitumor activity.

Targets

AURKB (Aurora kinase B)AURKA (Aurora kinase A)

Beyond the preview

Go deeper on ACTB1010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACTB1010.

Explore the full profile